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Abstract
Background: An early event in the neuropathology of prion and Alzheimer's diseases is the loss of synapses and a 
corresponding reduction in the level of synaptophysin, a pre-synaptic membrane protein essential for 
neurotransmission. The molecular mechanisms involved in synapse degeneration in these diseases are poorly 
understood. In this study the process of synapse degeneration was investigated by measuring the synaptophysin 
content of cultured neurones incubated with the prion derived peptide (PrP82-146) or with Aβ1-42, a peptide thought 
to trigger pathogenesis in Alzheimer's disease. A pharmacological approach was used to screen cell signalling 
pathways involved in synapse degeneration.
Results: Pre-treatment with phospholipase A2 inhibitors (AACOCF3, MAFP and aristolochic acids) protected against 
synapse degeneration in cultured cortical and hippocampal neurones incubated with PrP82-146 or Aβ1-42. Synapse 
degeneration was also observed following the addition of a specific phospholipase A2 activating peptide (PLAP) and 
the addition of PrP82-146 or Aβ1-42 activated cytoplasmic phospholipase A2 within synapses. Activation of 
phospholipase A2 is the first step in the generation of platelet-activating factor (PAF) and PAF receptor antagonists 
(ginkgolide B, Hexa-PAF and CV6029) protected against synapse degeneration induced by PrP82-146, Aβ1-42 and PLAP. 
PAF facilitated the production of prostaglandin E2, which also caused synapse degeneration and pre-treatment with 
the prostanoid E receptor antagonist AH13205 protected against PrP82-146, Aβ1-42 and PAF induced synapse 
degeneration.
Conclusions: Our results are consistent with the hypothesis that PrP82-146 and Aβ1-42trigger abnormal activation of 
cytoplasmic phospholipase A2 resident within synapses, resulting in elevated levels of PAF and prostaglandin E2that 
cause synapse degeneration. Inhibitors of this pathway that can cross the blood brain barrier may protect against the 
synapse degeneration seen during Alzheimer's or prion diseases.
Background
In the transmissible spongiform encephalopathies, other-
wise known as the prion diseases, changes in synaptic
function and a reduction in synaptophysin levels within
the brain occur at a time before any gross neuronal loss is
observed [1-3]. These synaptic alterations are associated
with the accumulation of a differentially folded, and pro-
tease-resistant isoform (PrPSc), of the host encoded cellu-
lar prion protein (PrPC) [4]. The formation of PrPSc is
accompanied by a decreased expression of proteins
involved in exocytosis and neurotransmission, such as
synaptophysin, SNAP-25 and synapsins in the brains of
scrapie-infected mice [2,5] and in humans affected with
Creutzfeldt-Jakob disease (CJD) [6].
The molecular mechanisms that underlie synapse
degeneration in prion diseases are not understood. Such
processes have been examined by incubating cultured
neurones with PrPSc or specific prion-derived peptides. A
major PrP fragment spanning amino acid residues 81-82
to 144-153 was isolated from the brains of patients with
the hereditary prion disease Gerstmann-Sträussler-Schei-
nker disease [7]. Synthetic peptides containing amino
acid residues 82 to 146 (PrP82-146) had similar structural
and biochemical properties to PrPSc suggesting that this
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fragment was the neurotoxic species generated in prion
diseases. This hypothesis was strengthened by observa-
tions that both partially purified PrPSc preparations and
PrP82-146 caused synapse degeneration in cortical and
hippocampal neurones [8]. The effect of PrP82-146 on
synapses in neuronal cultures was measured using an
enzyme linked immunoassay (ELISA) to quantify the
amount of synaptophysin [9]. Synaptophysin is a pre-syn-
aptic membrane protein essential for neurotransmitter
release and the recycling of synaptic vesicles and hence
neurotransmission [10-13]. The amount of synaptophysin
has been used to access synaptic density in the brain
[14,15] and in cultured neurones [8]. Although immuno-
cytochemistry is commonly used to examine synapse
density this method is susceptible to errors in counting
and field selection. The use of an ELISA overcame such
problems by measuring synaptic density throughout neu-
ronal cultures.
Synaptic failure is also thought to contribute to the neu-
ropathogenesis of Alzheimer's disease (AD) [16] and the
loss of synaptic proteins is the best correlate of dementia
in AD [14,17-20]. The amyloid hypothesis of AD patho-
genesis maintains that the primary event is the produc-
tion of neurotoxic amyloid-β (Aβ) peptides following the
proetolytic cleavage of the amyloid precursor protein into
different fragments [21,22]. These fragments include Aβ1-
42 which is widely regarded as the main pathogenic spe-
cies in AD. Recent studies showed the importance of
small soluble oligomers of Aβ or Aβ derived diffusible
ligands in neurotoxicity [23,24]. In this study we sought
to determine whether PrP82-146 and Aβ induced synapse
degeneration was mediated through specific cell signal-
ling pathways. We report that PrP82-146 and Aβ1-42
induced synapse degeneration was prevented by pharma-
cological inhibition of PLA2 and that both PrP82-146 and
Aβ1-42 peptides increased activation of cytoplasmic phos-
pholipase A2  (cPLA2) within synapses suggesting that
activation of this enzyme triggers synapse degeneration.
This hypothesis was supported by the observation that
the synapse degeneration was also observed following the
addition of a specific PLA2 activating peptide (PLAP).
Activation of PLA2 is the first step in the production of
bioactive prostaglandins and platelet-activating factor
(PAF), specific antagonists of which also reduced PrP82-
146 and Aβ1-42 induced synapse degeneration.
Results
PLA2 inhibitors protected against PrP82-146 induced 
synapse degeneration
The addition of the prion derived peptide PrP82-146
reduced the synaptophysin content of cortical neurones
indicative of a loss of synapses. This effect was a conse-
quence of the specific amino acid sequence of PrP82-146
as a control peptide (PrP82-146scram) did not affect syn-
apses [8]. The synaptophysin content was reduced by
greater than 80% by 1 μM PrP82-146 (Figure 1A) which
did not affect neuronal survival as measured by thiazyl
blue tetrazolium (98% neuronal survival ± 6 compared
with 100% ± 6, n = 9, P = 0.53). Immunoblot analysis
showed that PrP82-146 caused a dose-related reduction
in the amounts of synaptophysin in cell extracts without
affecting the amounts of β-actin (Figure 1B).
To determine if the degeneration of synapses resulted
from activation of specific cell signalling pathways corti-
cal neurones were pre-treated with inhibitors of some
common cell signalling pathways and incubated with
PrP82-146. Pre-treatment with the PLA2 inhibitors (1 μM
AACOCF3, 1 μM MAFP or 5 μg/ml aristolochic acids)
protected against the PrP82-146 mediated decrease in
synaptophysin (Figure 1A). The concentration of PrP82-
146 required to reduce the synaptophysin content of
vehicle treated cortical neurones by 50% (EC50) was
approximately 60 nM. By comparison, the EC50 of PrP82-
146 for cortical neurones treated with 1 μM AACOCF3 or
1 μM MAFP was greater than 10 μM, and in neurones
Figure 1 PLA2 inhibitors protected cortical neurones against 
PrP82-146 induced synapse degeneration. (A) The synaptophysin 
content of cortical neurones pre-treated for with a vehicle control (), 
1 μM AACOCF3 (), 1 μM MAFP (), 5 μg/ml aristolochic acid (), 10 
μM U73122 (Њ) or 10 μM ethyl-18-OCH3 () and subsequently incu-
bated with varying concentrations of PrP82-146 for 24 hours. Values 
shown are the mean average amount of synaptophysin ± standard de-
viation (SD), n = 15. (B) Immunoblots showing the amount of synapto-
physin and β-actin in cell extracts from neurones incubated with 
PrP82-146 (1.25 - 0.05 μM).Bate et al. Molecular Neurodegeneration 2010, 5:13
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pre-treated with 5 μg/ml aristolochic acids the EC50 was 5
μM. In contrast, pre-treatment with phospholipase C
inhibitors (10 μM U73122 or ethyl-18-OCH3) did not
affect the PrP82-146 induced loss of synaptophysin from
cortical neurones. The synaptophysin content of neu-
rones was not significantly affected by treatment with 5
μM AACOCF3 (100 units synaptophysin ± 4 compared to
101 ± 4, n = 12, P = 0.5), 5 μM MAFP (100 ± 4 v 102 ± 6, n
= 12, P = 0.4) or 5 μg/ml aristolochic acids (100 ± 4 com-
pared to 98 ± 4, n = 12, P = 0.2) alone showing that these
drugs did not stimulate synaptogenesis, nor did they
damage synapses.
PLA2 inhibitors protected hippocampal neurones against 
PrP82-146 induced synapse degeneration
To determine if the effect of PLA2 inhibitors was selective
for cortical neurones, their effect on hippocampal neu-
rones was also examined. PrP82-146 reduced the amount
of synaptophysin in hippocampal neurones; the EC50 of
PrP82-146 in hippocampal neurones was 10 nM and
while the addition of 200 nM PrP82-146 reduced the syn-
aptophysin content to 20% of control cultures, it did not
alter cell survival as measured by thiazyl blue tetrazolium
(97% cell survival ± 7 compared with 100% ± 9, n = 9, P =
0.7). Pre-treatment with 1 μM AACOCF3 or 1 μM MAFP
prevented the PrP82-146 mediated decrease in the synap-
tophysin content of hippocampal neurones and in treated
neurones the EC50 was increased to greater than 1 μM
(Figure 2).
PLA2 inhibitors protected against synapse degeneration 
induced by Aβ1-42
The synapse degeneration that occurs in AD is thought to
be caused by Aβ1-42 [25,26]. This process can be modelled
in vitro and the addition of Aβ1-42, but not Aβ42-1, reduced
the synaptophysin content of cultured cortical and hip-
pocampal neurones [27]. Here we report that pre-treat-
ment with 1 μM AA COCF 3 or 1 μM MAFP protected
cortical neurones against the Aβ1-42 induced reduction in
synaptophysin content (Figure 3A). While the EC50 of
Aβ1-42 in vehicle treated cortical neurones was 50 nM, the
EC50 of Aβ1-42 for cortical neurones treated with 1 μM
Figure 2 PLA2 inhibitors protected hippocampal neurones 
against PrP82-146 induced synapse degeneration. The synapto-
physin content of cultured hippocampal neurones pre-treated with a 
vehicle control (), 1 μM AACOCF3 () or 1 μM MAFP () and incubat-
ed with varying concentrations of PrP82-146 for 24 hours. Values 
shown are the mean average amount of synaptophysin ± SD, n = 9.
Figure 3 PLA2 inhibitors protected against Aβ1-42 induced syn-
apse degeneration. (A) The synaptophysin content of cortical neu-
rones pre-treated with a vehicle control (), 1 μM AACOCF3 () or 1 
μM MAFP () and incubated with varying concentrations of Aβ1-42 for 
24 hours. Values shown are the mean average amount of synapto-
physin ± SD, n = 12. (B) The synaptophysin content of hippocampal 
neurones pre-treated with a vehicle control () or 1 μM AACOCF3 () 
and incubated with varying concentrations of Aβ1-42 for 24 hours. Val-
ues shown are the mean average amount of synaptophysin ± SD, n = 6.Bate et al. Molecular Neurodegeneration 2010, 5:13
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AACOCF3 was greater than 10 μM. PLA2 inhibitors also
protected hippocampal neurones against Aβ1-42 induced
synapse degeneration. Thus, the EC50 of Aβ1-42 for vehicle
treated hippocampal neurones was 10 nM, while in hip-
pocampal neurones pre-treated with 1 μM AACOCF3 the
EC50 of Aβ1-42 was increased to greater than 1 μM (Figure
3B).
Conditioned medium from 7PA2 cells (7PA2-CM),
which contains naturally secreted Aβ oligomers [28], also
reduced the synaptophysin content of cortical neurones,
whereas conditioned medium from non-transfected Chi-
nese hamster ovary cells (CHO-CM), which did not con-
t a i n  A β  o l i g o m e r s ,  h a d  n o  a f f e c t  ( F i g u r e  4 A ) .  P r e -
treatment of cortical neurones with either 1 μM
AACOCF3  or 1 μM MAFP prevented the 7PA2-CM
mediated decrease in synaptophysin (Figure 4B).
PLA2 inhibitors did not affect the accumulation of PrP82-
146 in synapses
Prior studies showed that PrP82-146 accumulated within
synaptosomes isolated from cortical neurones prior to
synaptic degeneration [8]. That observation raised the
possibility that the protective effect of PLA2 inhibitors
might be because they reduced the binding/accumulation
of PrP82-146 within synapses. Firstly, we showed that the
amount of synaptophysin was not significantly different
between synaptosomes isolated from cortical neurones
and neurones treated 1 μM AACOCF3 or 1 μM MAFP;
indicating that these drugs did not affect synapse forma-
tion. Next cortical neurones were pre-treated with 1 μM
AACOCF3 before the addition of 100 nM PrP82-146. The
amount of PrP82-146 found within synaptosomes iso-
lated from vehicle and AACOCF3 treated neurones were
not significantly different (Figure 5). Similar results were
obtained with synaptosomes from cortical neurones pre-
treated with 1 μM MAFP indicating that the PLA2 inhibi-
tors did not prevent the binding or transport of PrP82-
146 to synapses.
Figure 4 PLA2 inhibitors protected against 7PA2-CM induced syn-
apse degeneration. (A) The synaptophysin content of cortical neu-
rones incubated for 24 hours with 7PA2-CM () or CHO-CM (). Values 
shown are the mean average amount of synaptophysin ± SD, n = 12. 
(B) The synaptophysin content of cortical neurones incubated for pre-
treated with a vehicle control (), 1 μM AACOCF3 () or 1 μM MAFP 
(striped bars) and incubated with doubling dilutions of 7PA2-CM for 24 
hours. Values shown are the mean average amount of synaptophysin 
± SD, n = 12.
Figure 5 PLA2 inhibitors did not affect the accumulation of PrP82-
146 in synapses. The amount of PrP82-146 detected in synaptosomes 
isolated from cortical neurones incubated with a vehicle control (), 1 
μM AACOCF3 () or 1 μM MAFP (striped bars). Treated cortical neu-
rones were incubated with 100 nM PrP82-146 for the time periods 
shown. Synaptosomes were isolated from neuronal cultures and the 
amount of PrP82-146 was measured by ELISA. Values shown are the 
mean average amount of PrP82-146 (nM) ± SD, n = 9.Bate et al. Molecular Neurodegeneration 2010, 5:13
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PLA2 inhibitors protected against synapse degeneration 
induced by PLAP
Next we sought to determine whether synapse degenera-
t i o n  r e s u l t e d  f r o m  a c t i v a t i o n  o f  a n  e n d o g e n o u s  P L A 2.
The addition of PLAP, a peptide that activated endoge-
nous cPLA2 [29,30], had similar effects as PrP82-146 and
Aβ1-42 on synapses; it reduced the synaptophysin content
of cortical neurones in a dose dependent manner. The
addition of 1 μM PLAP reduced the synaptophysin con-
tent of cultured neurones by approximately 80% without
affecting the survival of neurones as measured by thiazyl
blue tetrazolium (96% neuronal survival ± 5 compared
with 100% ± 8, n = 9, P = 0.7). Pre-treatment with 1 μM
AACOCF3 or 1 μM MAFP protected cortical neurones
against PLAP induced synapse degeneration; in vehicle
treated neurones the EC50 of PLAP was 100 nM, while in
neurones pre-treated with 1 μM AACOCF3 or 1 μM
MAFP the addition of 1 μM PLAP did not reduce the syn-
aptophysin content by more than 20% (Figure 6).
cPLA2 is enriched in synaptosomes
To investigate the hypothesis that synapse degeneration
resulted from activation of an endogenous cPLA2, the
amount of cPLA2 protein in synaptosomes was measured.
The cPLA2 protein was enriched in synaptosomes iso-
l a t e d  f r o m  c o r t i c a l  n e u r o n e s  c o m p a r e d  t o  w h o l e  c e l l
membrane extracts (100 units cPLA2/mg protein ± 31
compared to 6 units/mg ± 1, n = 12, P < 0.01). There were
no significant differences in the amount of total cPLA2
protein in synaptosomes isolated from vehicle treated
cortical neurones and those treated for 1 hour with 200
nM PrP82-146, 200 nM PrP82-146scrambled, 1 μM
PLAP, 100 nM Aβ1-42 or 100 nM Aβ42-1 (Table 1). Mea-
surements were made after 1 hour, before any synapse
degeneration was observed. Next specific antibodies (to
cPLA2 phosphorylated at serine 505) were used to deter-
mine the amount of activated cPLA2  within synapto-
somes. The amount of activated cPLA2  within
synaptosomes was significantly increased following the
addition of 200 nM PrP82-146, 1 μM PLAP or 100 nM
Aβ1-42 but not after the addition of PrP82-146scrambled
or Aβ42-1 (Table 1). Moreover, there was a significant
inverse correlation between the amount of activated
cPLA2in synaptosomes after 1 hour and the amount of
synaptophysin in neurones after 24 hours following the
addition of different amounts of PrP82-146 (range 1.25 to
.005 μM), Pearson's coefficient = -0.76, P < 0.01 (Figure
7).
PAF antagonists protected against PrP82-146 induced 
synapse degeneration
The activation of PLA2 is the first step in the production
of PAF [31] that has been shown to cause synapse degen-
eration in vitro [27]. The addition of PAF receptor antag-
onists (Hexa-PAF, CV6209 or ginkgolide B), in the range
0.1-10 μM, did not affect the amount of synaptophysin in
cortical neurones. However, pre-treatment with 2 μM
Hexa-PAF, 2 μM CV6209 or 1 μM ginkgolide B provided
protection against PrP82-146 induced synapse degenera-
tion (Figure 8). The EC50 of PrP82-146 in vehicle treated
cortical neurones was 50 nM while the EC50 of PrP82-146
for neurones treated with 2 μM Hexa-PAF was 2 μM, for
neurones treated with 2 μM CV6209 the EC50 was 5 μM
and for neurones pre-treated with 1 μM ginkgolide B the
EC50 was 20 μM. Pre-treatment with Hexa-PAF, gink-
golide or CV6209 also prevented the reduction in the
synaptophysin content of cortical neurones incubated
with 100 nM Aβ1-42 or 1 μM PLAP (Table 2). In a similar
manner, the amount of synaptophysin in hippocampal
neurones incubated with 50 nM PrP82-146 was signifi-
cantly increased by pre-treatment with 1 μM ginkgolide B
(97 units synaptophysin ± 9 compared to 18 ± 7, n = 6, P <
0.01), 2 μM Hexa-PAF (94 ± 11 compared to 18 ± 7, n = 6,
P < 0.01) or 2 μM CV6209 (94 ± 11 compared to 18 ± 7, n
= 6, P < 0.01).
Prostaglandin E2 induced synapse degeneration
Prior studies showed that PAF facilitates the production
of prostaglandins [32] suggesting that one or more of the
prostaglandins produced in response to PrP82-146, Aβ1-
Figure 6 PLA2 inhibitors protected against PLAP induced synapse 
degeneration. The synaptophysin content of cortical neurones pre-
treated with a vehicle control (), 1 μM AACOCF3 () or 1 μM MAFP 
() and incubated with varying concentrations of PLAP for 24 hours. 
Values shown are the mean average amount of synaptophysin ± SD, n 
= 12.Bate et al. Molecular Neurodegeneration 2010, 5:13
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42 or PLAP are responsible for synapse degeneration. This
hypothesis was tested by treating cortical neurones with
individual prostaglandins. We report that the addition of
prostaglandin E2, but not other prostaglandins reduced
the amount of synaptophysin in cortical neurones (Figure
9). Prostaglandin E2, acts via specific prostanoid E recep-
tors [33] and pre-treatment with the prostanoid E recep-
tor antagonist AH13205, but not the prostanoid D
receptor antagonist BWA868C, prevented the loss of syn-
aptophysin in cortical neurones incubated with PrP82-
146, Aβ1-42, PLAP, PAF or prostaglandin E2 (Table 3).
Taken together, these results show that the effects of
PrP82-146 or Aβ1-42 on synapses were ultimately medi-
ated through prostanoid E receptors.
Discussion
The addition of PrP82-146 reduced the synaptophysin
content of cortical neurones indicative of a loss of syn-
apses. This occurred at concentrations of peptide that did
not affect neuronal survival [8], results consistent with in
vivo observations that the loss of synapses in prion dis-
eases occurs before any significant neuronal death is seen
[1,2]. PrP82-146 also damaged synapses in hippocampal
neuronal cultures. The hippocampus is involved in mem-
ory formation and the loss of synapses in this area is con-
sistent with the cognitive deficits that occur during the
early stages of scrapie infections [3,34].
A pharmacological approach was used to examine the
molecular mechanisms involved in prion induced syn-
apse degeneration. Critically, pre-treatment with selec-
tive PLA2 inhibitors reduced PrP82-146 induced synapse
degeneration, whereas pre-treatment with inhibitors of
some other common cell signalling pathways including
phospholipase C had no affect. PrPSc is detected within
synapses in CJD patients and experimental scrapie infec-
tions [2,35,36] and PrP82-146 was found within synapto-
somes isolated from cultured neurones [8]. We found that
pre-treatment with PLA2  inhibitors did not alter the
Table 1: PrP82-146 and Aβ1-42activated cPLA2within synapses.
Treatment Total cPLA2 protein
(units/mg protein)
Activated cPLA2
(units/mg protein)
None (units) 100 ± 31 100 ± 19
200 nM PrP82-146 106 ± 18 773 ± 51 *
200 nM PrP82-146scrambled 95 ± 22 111 ± 34
1 μM PLAP 119 ± 30 928 ± 84 *
100 nM Aβ1-42 109 ± 21 655 ± 62 *
100 nM Aβ42-1 92 ± 27 121 ± 34
Primary cortical neurones were incubated with PrP, Aβ or PLAP peptides as shown for 1 hour. Synaptosomes were subsequently isolated from 
treated neurones and the amount of cPLA2 protein, and the amount of activated cPLA2 (phosphorylated at serine 505) were measured by 
ELISA. Values shown are the mean average amount of cPLA2 protein or activated cPLA2 (units/mg protein) ± SD, n = 12. * = amount of 
activated cPLA2 significantly greater than in control synaptosomes.
Figure 7 PrP82-146 increased activation of cPLA2 in synapses. 
Correlation between the amounts of activated cPLA2 in synaptosomes 
isolated from primary cortical neurones 1 hour after the addition of 
varying concentrations of PrP82-146 and the amount of synapto-
physin in cell extracts from primary cortical neurones incubated for 24 
hours with the same concentrations of PrP82-146.Bate et al. Molecular Neurodegeneration 2010, 5:13
http://www.molecularneurodegeneration.com/content/5/1/13
Page 7 of 12
amount of PrP82-146 found within synaptosomes, indi-
cating the protective effect of these drugs was not due to
the reduced binding of PrP82-146 to synaptic receptors,
or a reduction in the trafficking of PrP82-146 to synapses.
Next, the possibility that PrP82-146 might activate
cPLA2 resident within synapses was examined. Previous
studies reported that PLA2 was found at synapse and reg-
ulated synaptic vesicle recycling [37,38] and we observed
that cPLA2 was highly enriched in synaptosomes. These
observations imply that cPLA2 is part of the normal func-
tion of synapses and complete inhibition of cPLA 2 may
not be desirable as it may interfere with neurotransmis-
sion. However, the addition of PrP82-146 increased the
amount of activated cPLA2 within synaptosomes nearly 8
fold suggesting that PrP82-146 induced activation of
cPLA2 resident within synapses was responsible for syn-
apse degeneration. This hypothesis was supported by our
observations that there was a significant inverse correla-
tion between the amount of activated cPLA2 and synaptic
density and that synapse degeneration was also observed
after the addition of PLAP. In addition, the effect of both
PLAP and PrP82-146 on synapses was greatly reduced by
pre-treatment with the cPLA2 inhibitors AACOCF3 and
MAFP. Collectively, these results strongly suggesting that
activation of an endogenous cPLA2 is a pivotal event in
PrP82-146 mediated synapse degeneration.
The activation of PLA2 leads to the formation of a num-
ber of bioactive factors including prostaglandins, leucot-
rienes, docosanoids and PAF [31,39]. PAF receptors are
present at synaptic endings [40] and PAF facilitates neu-
rotransmission [41]. However, higher concentrations of
PAF are implicated in the neurotoxicity of glutamate,
human immunodeficiency virus infection, prion diseases
and AD [39,42]. Reports that synaptic activity becomes
excitotoxic in neurones exposed to elevated levels of PAF
[43] may explain the role of PAF in these diseases. Here
we showed that synapse degeneration induced by PrP82-
146 was reduced by pre-treatment with PAF receptor
antagonists, ginkgolide B, Hexa-PAF and CV6209. These
PAF receptor antagonists also reduced synapse degenera-
tion induced by PLAP suggesting that the effect of PrP82-
146 and PLAP were a secondary effect mediated by acti-
va t ion o f  an endog en ous  cPLA 2 and the production of
PAF.
PAF affects the production of prostaglandin E2 [32]
which is found in close association with PrPSc deposition
and neuronal degeneration in scrapie [44]. In addition,
the levels of prostaglandin E2are raised in the cerebrospi-
nal fluid of patients with CJD [45]. While prostaglandin
Table 2: PAF receptor antagonists reduced synapse degeneration induced by Aβ1-42or PLAP.
Synaptophysin (units/106cells)
Treatment Vehicle Hexa-PAF Ginkgolide B CV6209
Vehicle 100 ± 6 98 ± 7 102 ± 5 96 ± 8
100 nM Aβ1-42 32 ± 6 94 ± 6 98 ± 9 89 ± 8
1 μM PLAP 27 ± 7 95 ± 8 94 ± 8 82 ± 7
Primary cortical neurones were pre-treated with a vehicle control, or with PAF receptor antagonists (2 μM Hexa-PAF, 1 μM ginkgolide or 2 μM 
CV6209) for 1 hour prior to incubation with Aβ1-42 or PLAP as shown for 24 hours. Values shown are the mean average amount of 
synaptophysin (units/106 cells) ± SD, n = 12.
Figure 8 PAF receptor antagonists protected against PrP82-146 
induced synapse degeneration. The synaptophysin content of corti-
cal neurones pre-treated with a vehicle control (), 1 μM ginkgolide B 
(), 2 μM Hexa-PAF () or 2 μM CV6209 () and subsequently incu-
bated with varying concentrations of PrP82-146 for 24 hours. Values 
shown are the mean average amount of synaptophysin ± SD, n = 12.Bate et al. Molecular Neurodegeneration 2010, 5:13
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E2 may modify hippocampal synaptic transmission via a
pre-synaptic prostanoid E receptors [46], higher concen-
trations cause synapse degeneration [27]. As shown in
Figure 9 the addition of prostaglandin E2, but not other
prostaglandins, caused synapse degeneration. The effects
of prostaglandin E2 are mediated by specific membrane
bound prostanoid E receptors [47] and synapse degenera-
tion induced by PrP82-146 was reduced by pre-treatment
with the prostanoid E receptor antagonist AH13205 sug-
gesting that its effect was mediated through the pros-
tanoid E receptor.
The results presented here may also be pertinent for
other diseases in which synapse degeneration is common.
For example, the neurotoxicity of Aβ1-42, widely believed
to be the main toxin responsible for neurodegeneration in
AD [23,48-50], was reduced following knockdown on
cPLA2  [51,52]. In this study we showed that Aβ1-42
strongly activated cPLA2 within synapses and that pre-
treatment with PLA2 inhibitors protected against the syn-
apse degeneration induced by Aβ1-42and naturally
secreted Aβ oligomers (7PA2-CM). This observation is
consistent with reports that inhibition of cPLA2 protected
against cognitive impairment in a mouse model of AD
[53]. A recent study indicated that PrPC acts as a receptor
for Aβ1-42 oligomers [54]. PrPC also acts as a receptor for
PrP peptides [55] suggesting that both PrP and Aβ1-42
activate PLA2 through their interaction with PrPC. We
note that oligomers, rather than monomers, of PrP or
Aβ1-42 are neurotoxic [56-58]. Since oligomers of PrP and
Aβ1-42, but not monomers, have the capacity to cross-link
PrPC, our results support the hypothesis that it is the
cross-linkage of PrPC by PrP or Aβ1-42 oligomers that acti-
vated cPLA2 leading to the production of PAF and prosta-
glandins. We propose that it is the persistent activation of
cPLA2 by PrP82-146 or Aβ1-42 that results in high concen-
Table 3: A prostanoid E receptor antagonist protected against synapse degeneration
Synaptophysin (units)
Treatment Vehicle control Prostanoid E receptor 
antagonist AH13205
Prostanoid D receptor 
antagonist BWA868C
Vehicle control 100 ± 6 99 ± 7 99 ± 3
200 nM PrP82-146 22 ± 5 87 ± 8 30 ± 7
100 nM Aβ1-42 32 ± 6 93 ± 5 34 ± 6
1 μM PLAP 27 ± 7 91 ± 7 38 ± 6
10 nM PAF 31 ± 4 85 ± 9 32 ± 5
10 nM Prostaglandin E2 30 ± 5 97 ± 3 33 ± 6
Primary cortical neurones were pre-treated with a vehicle control, a prostanoid E receptor antagonist (100 nM AH13205) or a prostanoid D 
receptor antagonist (100 nM BWA868C) for 1 hour prior to incubation with PrP82-146, Aβ1-42, PLAP, PAF or prostaglandin E2 as shown for 24 
hours. Values shown are the mean average amount of synaptophysin ± SD, n = 9.
Figure 9 Prostaglandin E2 caused synapse degeneration. The syn-
aptophysin content of cortical neurones treated with varying concen-
trations of prostaglandins E2 () D2 (), F2α(), I2 () or 15d-J2 (Њ) for 
24 hours. Values shown are the mean average amount of synapto-
physin ± SD, n = 9.Bate et al. Molecular Neurodegeneration 2010, 5:13
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Page 9 of 12
trations of PAF and prostaglandin E2 that cause synapse
degeneration [27,43].
Conclusion
Drugs that protect the synapse provide a rational strategy
to treat many neurodegenerative diseases. In this study
w e  s ho wed t ha t  PLA 2 inhibitors, PAF receptor antago-
nists and a prostanoid E receptor antagonist all protected
against the synapse degeneration induced by PrP82-146
or Aβ1-42 in vitro. These peptides did not have a direct
effect on synapses; rather synapse degeneration was
caused after PrP82-146 or Aβ1-42 induced activation of an
endogenous cPLA2 and the production of PAF and pros-
taglandin E2. Such results suggest that specific cPLA2
inhibitors or PAF receptor antagonists that are able to
cross the blood-brain barrier should be considered for
further testing in animal models of prion and Alzheimer's
diseases.
Methods
Primary neuronal cultures
Primary cortical neurones were prepared from the brains
of mouse embryos (day 15.5). Neuronal precursors were
plated at 2 × 105 cells/well in 48 well plates in Ham's F12
containing 5% foetal calf serum (FCS) for 2 hours. Cul-
tures were shaken (600 r.p.m for 5 minutes) and non-
adherent cells removed by 3 washes in phosphate buff-
ered saline (PBS). Neurones were grown in neurobasal
medium (NBM) containing B27 components (PAA) for 7
days. Immunohistochemistry showed that the cells were
greater than 97% neurofilament positive. Less than 3%
stained for GFAP (astrocytes) or for F4/80 (microglial
cells). Hippocampal neurones were prepared from the
brains of adult mice as described [59]. Briefly, hip-
pocampi were dissected and triturated in Ham's F12 con-
taining 5% FCS, 0.35% glucose, 0.025% trypsin, and 0.1%
type IV collagenase. After 30 minutes at 37°C, the cells
were triturated again and the cell suspension was passed
through a 100 μM cell strainer. Cells were collected by
centrifugation, washed twice in Ham's F12 containing 5%
FCS and plated at 2 × 105 cells/well in 48 well plates for 24
hours. Cultures were shaken (600 r.p.m for 5 minutes) to
remove non-adherent cells, washed twice with PBS and
neurones were cultured in NBM containing B27 compo-
nents and 10 ng/ml glial-derived neurotrophic factor
(Sigma) for 10 days. Neurones were incubated with test
compounds for 3 hours before the addition of peptides
and the amount of synaptophysin in treated neurones was
measured 24 hours later. The survival of neurones was
determined 5 days later using 25 μM thiazlyl blue tetrazo-
lium for 3 hours; neuronal survival was reported as a per-
centage of controls (vehicle treated neurones).
Cell extracts
Neurones were homogenised in a buffer containing 150
mM NaCl, 10 mM Tris-HCl, 10 mM EDTA, 0.5% Nonidet
P-40, 0.5% sodium deoxycholate and mixed protease
inhibitors (AEBSF, Aprotinin, Leupeptin, Bestain, Pepsta-
tin A and E-46 (Sigma)) and a phosphatase inhibitor
cocktail including PP1, PP2A, microcystin LR, canthari-
din and p-bromotetramisole (Sigma) at 106  cells/ml.
Nuclei and cell debris was removed by low speed centrif-
ugation (300 × g for 5 minutes). For immunoblots, cells
were mixed 1:1 with Laemmli buffer containing β-mer-
captoethanol, boiled for 5 minutes and run on a 12%
polyacrylamide gel. Proteins were transferred onto a
Hybond-P PVDF membrane (Amersham Biotech) by
semi-dry blotting. Membranes were blocked using 10%
milk powder; synaptophysin was detected using a mouse
monoclonal antibody (mAb) anti-synaptophysin SY38
(Abcam) and β-actin was detected by incubation with a
mouse mAb (clone AC-74, Sigma). These were visualised
using a combination of biotinylated rabbit anti-mouse
IgG (Dako), extravidin-peroxidase and an enhanced
chemiluminescence kit (Invitrogen).
Synaptophysin ELISA
Synaptophysin levels in cell extracts were measured by
ELISA as described [9,27]. A mouse monoclonal anti-
synaptophysin MAB368 (Millipore) was used as a capture
antibody and bound synaptophysin was detected using
rabbit polyclonal anti-synaptophysin (Abcam) followed
by a biotinylated anti-rabbit IgG, extravidin-alkaline
phosphatase and 1 mg/ml 4-nitrophenol phosphate
(Sigma). Absorbance was measured on a microplate
reader at 405 nm and synaptophysin content was calcu-
lated from a standard curve. Samples were expressed as
"units synaptophysin" where 100 units was defined as the
amount of synaptophysin in 106 vehicle treated neurones.
A standard curve was generated from this sample using
sequential log 2 dilutions (range 100 to 1.56 units).
Synaptosome preparations
Cortical neurones were pre-treated with drugs for 3
hours prior to the addition of 100 nM PrP82-146. After
different time points (10, 30, 60 or 90 minutes) neurones
were washed 3 times to remove unbound peptide and
synaptosomes prepared on a discontinuous Percoll gradi-
ent as described [60]. Briefly, 106 cortical neurones were
homogenized at 4°C in 1 ml of SED solution (0.32 M
sucrose, 50 mM Tris-HCl, 1 mM EDTA, and 1 mM
dithiothreitol, pH 7.4 and mixed protease/phosphates
inhibitors (as above)). The preparation was centrifuged at
1000 × g for 10 minutes. The supernatant was transferred
to a 4-step gradient of 3, 7, 15, and 23% Percoll in SED
solution and centrifuged at 16,000 × g for 30 minutes atBate et al. Molecular Neurodegeneration 2010, 5:13
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4°C. The synaptosome fraction was collected from the
interface of the 15% and 23% Percoll steps, washed twice
(16,000 × g  for 30 minutes at 4°C) and suspended in
extraction buffer (150 mM NaCl, 10 mM Tris-HCl, 10
mM EDTA, 0.2% SDS and mixed protease/phosphatase
inhibitors).
PrP82-146 ELISA
The amount of PrP82-146 in synaptosomes was deter-
mined by ELISA. Nunc Maxisorb Immunoplates were
coated with 0.5 μg/ml of mouse mAb 3F4 (reactive with
residues 109-112 of human PrP (Abcam)) this mAb does
not bind to murine PrP [61]. Samples were applied and
PrP82-146 was detected with 0.5 μg/ml biotinylated
ICSM35 (D-gen, http://www.d-gen.co.uk), followed by
streptavidin-alkaline phosphatase (Dako) and 1 mg/ml 4-
nitrophenyl phosphate (Sigma). Absorbance was mea-
sured on a microplate reader at 405 nm and the amount
of PrP82-146 in cell extracts was calculated by reference
to a standard curve of PrP82-146.
cPLA2 ELISA
The amount of cPLA2 in synaptosomes was measured by
ELISA [62]. Nunc Maxisorb Immunoplates were coated
with 0.5 μg/ml of mouse mAb anti-cPLA2, clone CH-7
(Upstate) and blocked with 10% FCS. Samples were incu-
bated for 1 hour and the amount of cPLA2 was detected
using a goat polyclonal anti-cPLA2 (Santa-Cruz Biotech).
Bound antibodies were detected with biotinylated anti-
goat IgG, extravidin-alkaline phosphatase and 1 mg/ml 4-
nitrophenyl phosphate. Absorbance was measured at 405
nm and the amount of cPLA2 was calculated from a stan-
dard curve using nonlinear regression. The amount of
cPLA2  protein was expressed in units (100 units =
amount of cPLA2  in synaptosomes isolated from 106
untreated primary cortical neurones). The activation of
cPLA2 is accompanied by phosphorylation of the 505 ser-
ine residue which creates a unique epitope. To measure
the amount of activated cPLA2, an ELISA using a mAb
(anti-cPLA2, clone CH-7) combined with rabbit poly-
clonal anti-phospho-cPLA2 (Cell Signalling Technology)
was used. Bound antibodies were detected with biotiny-
lated anti-rabbit IgG (Dako), extravidin-alkaline phos-
phatase and 1 mg/ml 4-nitrophenyl phosphate. Samples
were expressed as "units activated cPLA2" where 100
units were defined as the amount of activated cPLA2 in
synaptosomes derived from 106 untreated primary corti-
cal neurones.
Drugs
U73122 and Ethyl-18-OCH3 were obtained from Biomol.
Arachidonyl trifluoromethyl ketone (AACOCF3), aristo-
lochic acids, ginkgolide B, 1-O-Hexadecyl-2-acetyl-sn-
glycerol-3-phospho-(N,N,N-trimethyl)-hexanolamine
(Hexa-PAF), methyl arachidonyl fluorophosphonate
(MAFP), prostaglandin G2, AH13205 and BWA868C
were obtained from Sigma. Prostaglandins 15d-J2, E2, D2,
F2α, H2 and I2 were obtained from Novabiochem. Stock
solutions were dissolved in ethanol or di-methyl sulphox-
ide (DMSO) and diluted in medium to obtain final work-
ing concentrations. Vehicle controls consisted of
equivalent dilutions of ethanol or DMSO in NBM.
Peptides
Peptides containing amino acids 82 to 146 of the human
PrP protein (PrP82-146) corresponding to a PrP fragment
found in certain prion-infected human brains [7], a con-
trol peptide (PrP82-146scrambled) were synthesised by
solid-phase chemistry and purified by reverse-phase high
performance liquid chromatography. A synthetic peptide
containing the amino acid residues 1 to 42 of Aβ (Aβ1-42)
of the Aβ protein and a control peptide consisting of the
same amino acids in reverse order (Aβ42-1) were obtained
from Bachem. Aβ peptides were first dissolved in
hexafluoroisopropanol, lyophilised and subsequently sol-
ubilised and stored in DMSO. PLA2 Activating Peptide
(PLAP) was purchased from Bachem. Stock solutions of
peptides were thawed on the day of use and sonicated
before dilution in culture medium and addition to cells.
CHO cells stably transfected with a cDNA encoding
APP751 containing the Val717Phe familial AD mutation
(referred to as 7PA2 cells) were cultured in DMEM with
10% FCS [28]. Conditioned medium (CM) from these
cells contains stable Aβ oligomers (7PA2-CM). Condi-
tioned medium from non-transfected CHO cells (CHO-
CM) was used as controls.
Statistical Methods
Differences between treatment groups were assessed
using two sample t tests or analysis of variance tech-
niques. In all tests statistical significance was set at the 1%
level.
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